Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading & Demat Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Comparision between Emcure Pharma IPO and Manyavar IPO.
Emcure Pharma IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Manyavar IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
| Emcure Pharma IPO | Manyavar IPO | |
|---|---|---|
| Logo |  |
 |
| Issue Category | Mainline | Mainline |
| Issue Type | IPO | IPO |
| Process Type | Book Built Issue | Book Built Issue |
| Listing At | BSE, NSE | BSE, NSE |
| Lead Managers | Kotak Mahindra Capital Company Limited Axis Capital Limited Jefferies India Private Limited J.P. Morgan India Private Limited |
Axis Capital Limited Edelweiss Financial Services Ltd ICICI Securities Limited Iifl Securities Ltd Kotak Mahindra Capital Company Limited |
| Registrar | Link Intime India Private Ltd | Kfin Technologies Limited |
| Market Maker | ||
| DRHP | DRHP  |
DRHP |
| RHP | RHP |
|
| Anchor Investor | Anchor Investor |
|
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Emcure Pharma IPO is whereas the issue size of the Manyavar IPO is up to ₹3,149.19 Cr. The final issue price of Emcure Pharma IPO is and of Manyavar IPO is ₹866.00 per share.
| Emcure Pharma IPO | Manyavar IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹1 per share |
| Issue Price (Lower) | ₹824.00 per share | |
| Issue Price (Upper) | ₹866.00 per share | |
| Issue Price (Final) | ₹866.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 17 shares | |
| Fresh Issue Size | ||
| Fresh Issue Size (Amount) | up to ₹800.00 Cr | |
| OFS Issue Size | 1,36,78,839 shares | 3,63,64,838 shares |
| OFS Issue Size (Amount) | up to ₹3,149.19 Cr | |
| Issue Size Total | 3,63,64,838 shares | |
| Issue Size Total (Amount) | up to ₹3,149.19 Cr |
Emcure Pharma IPO opens on , while Manyavar IPO opens on Feb 04, 2022. The closing date of Emcure Pharma IPO and Manyavar IPO is , and Feb 08, 2022, respectively.
| Emcure Pharma IPO | Manyavar IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Feb 04, 2022 | |
| Issue Close | Feb 08, 2022 | |
| Basis Of Allotment (Tentative) | Feb 11, 2022 | |
| Initiation of Refunds (Tentative) | Feb 14, 2022 | |
| Credit of Share (Tentative) | Feb 15, 2022 | |
| Listing date (Tentative) | Feb 16, 2022 | |
| Anchor Lockin End date 1 | Mar 13, 2022 | |
| Anchor Lockin End date 2 | May 12, 2022 |
Emcure Pharma IPO P/E ratio is , as compared to Manyavar IPO P/E ratio of 106.78.
| Emcure Pharma IPO | Manyavar IPO | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financial |
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.40% | |||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 84.9% | |||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 106.78 | |||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹21017.37 Cr. | |||||||||||||||||||||||||||||||||||||||||||||
| ROE | ||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | ||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | ||||||||||||||||||||||||||||||||||||||||||||||
In the Emcure Pharma IPO retail investors (RII) are offered while in Manyavar IPO retail investors are offered . Qualified institutional buyers (QIB) are offered in Emcure Pharma IPO and 72,72,968 shares in Manyavar IPO.
| Emcure Pharma IPO | Manyavar IPO | |
|---|---|---|
| Anchor Investor Reserveration | ||
| Market Maker Reserveration | ||
| QIB | 72,72,968 shares | |
| NII | 54,54,726 shares | |
| RII | 1,27,27,694 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 2,54,55,388 shares |
Emcure Pharma IPO subscribed in total, whereas Manyavar IPO subscribed 2.57x.
| Emcure Pharma IPO | Manyavar IPO | |
|---|---|---|
| QIB (times) | 7.49x | |
| NII (times) | 1.07x | |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 0.39x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 2.57x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
